Table 2 Susceptibility of the infectious agents found in 268 samples of ascitic fluid to different antimicrobials during the period 2010-2011
Total (n = 268) | After exclusion of coagulase negative staphylococci (n = 195) | Non-nosocomial episodes (n = 109) | Nosocomial episodes (n = 159) | P1 | SBP (n = 57) | Bacterascites (n = 140) | P 2 | |
|---|---|---|---|---|---|---|---|---|
Amoxicillin | 33.2% | 45.6% | 40.4% | 28.3% | 0.04 | 40.4% | 33.3% | 0.37 |
Amoxicillin + clavulanate | 42.5% | 53.3% | 50.5% | 38.1% | 0.02 | 43.9% | 44.3% | 0.96 |
Broad-spectrum penicillin | 35.4% | 48.7% | 38.5% | 33.3% | 0.38 | 40.4% | 39.3% | 0.89 |
Broad-spectrum penicillin + beta lactamase inhibitor | 48.1% | 64.1% | 51.4% | 45.9% | 0.38 | 47.4% | 50.7% | 0.67 |
Third-generation cephalosporin | 39.2% | 39.0% | 55.0% | 28.3% | <0.0001 | 33.3% | 42.1% | 0.25 |
Fluoroquinolone | 46.6% | 46.7% | 57.8% | 39.0% | 0.002 | 38.6% | 47.1% | 0.27 |
Aminoglycoside | 50.0% | 47.2% | 56.9% | 45.3% | 0.06 | 47.4% | 52.9% | 0.48 |
Cotrimoxazole | 42.2% | 38.4% | 53.2% | 34.6% | 0.002 | 29.8% | 45.7% | 0.04 |
Glycopeptide | 57.8% | 45.6% | 60.6% | 56.0% | 0.45 | 50.9% | 66.5% | 0.04 |